AKT1 and cancer: Similarly, a novel topo II inhibitor MFTZ-1 reduced HIF-1α accumulation driven by hypoxia or growth factors in human cancer cells, possibly through the inhibition of PI3K-Akt and MAPK pathways, eliciting anti-angiogenesis independently of its topo II inhibition[43].